Your Messages Inbox
Your Article Summary
See Latest ArticlesNovartis MF59 adjuvanted cell culture-based vaccine shows strong immune response in A(H1N1) clinical trials
Novartis, 09/04/09
A pilot trial of Novartis adjuvanted cell culture–based A(H1N1) vaccine[1] indicates that the "swine flu" vaccine elicited a strong immune response and was well tolerated. The trial was run by the UK's University of Leicester and University Hospitals of Leicester. The vaccine, to be called Celtura, was tested with 100 healthy volunteers, aged between 18 and 50.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
Investigational New Drugs, 12/17/09
Prognostic Factors in Idiopathic Pulmonary Fibrosis
The American Journal of the Medical Sciences, 12/17/09
Milatuzumab – a promising new immunotherapeutic agent
Expert Opinion on Investigational Drugs, 12/17/09
Article Search
Sponsor